Numab Therapeutics Appoints Rajesh Chopra as Chief Scientific Officer
PRIVATEOct 01, 2026
Position
Chief Scientific Officer
Company
Numab Therapeutics
Rajesh Chopra, M.D., PhD
HorgenBiotechnologyHealth CareTherapeutics
Description
Numab Therapeutics has appointed Rajesh Chopra, M.D., PhD, as Chief Scientific Officer. With nearly four decades of experience in oncology and immunology, Dr. Chopra will enhance the company's scientific leadership and advance its innovative pipeline.
Company Information
Company
Numab Therapeutics
Location
Horgen, Zurich, Switzerland
About
Numab Therapeutics is developing multi-specific antibody-based immunotherapies for inflammation and cancer. Reproducible plug-and-play therapeutic design process using proprietary platforms λ-Cap™ and MATCH™ puts Numab in a unique position to overcome historical drug discovery barriers and build a pipeline of first-in-class and best-in-class medicines aimed to maximize patient benefits.
Our lead candidate NM26, a unique multi-specific targeting IL-4/13 and IL-31 for best-in-class efficacy, is developed with a vision of delivering a lifelong cure to patients suffering from atopic dermatitis (AD) and other potential indications.
Fundz sees it the moment Numab Therapeutics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
HorgenBiotechnologyHealth CareTherapeutics